Literature DB >> 17610072

[Nephrogenic systemic fibrosis. Medical detective work in the 21st century].

B Manger1.   

Abstract

Nephrogenic systemic fibrosis is a new disease entity which was first described in 2000. It is characterized by dermal and visceral fibrosis in patients with impaired renal function. Recently, the etiology of this disease has been unveiled. The application of gadolinium-containing contrast media in patients with decreased renal function can lead to gadolinium deposition in various tissues which induces the fibrotic process. Numerous publications within the last few months have supported this hypothesis and have led to recommendations by the health authorities to carefully weigh the benefits and risks of using gadolinium in patients with impaired renal function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17610072     DOI: 10.1007/s00393-007-0186-0

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  25 in total

1.  Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents--St. Louis, Missouri, 2002-2006.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2007-02-23       Impact factor: 17.586

2.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

3.  Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis--setting the record straight.

Authors:  Shawn E Cowper; Richard Bucala; Philip E Leboit
Journal:  Semin Arthritis Rheum       Date:  2006-02       Impact factor: 5.532

Review 4.  Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency.

Authors:  Rush H Chewning; Kieran J Murphy
Journal:  J Vasc Interv Radiol       Date:  2007-03       Impact factor: 3.464

5.  Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned.

Authors:  Dale R Broome; Mark S Girguis; Pedro W Baron; Alfred C Cottrell; Ingrid Kjellin; Gerald A Kirk
Journal:  AJR Am J Roentgenol       Date:  2007-02       Impact factor: 3.959

6.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.

Authors:  Peter Marckmann; Lone Skov; Kristian Rossen; Anders Dupont; Mette Brimnes Damholt; James Goya Heaf; Henrik S Thomsen
Journal:  J Am Soc Nephrol       Date:  2006-08-02       Impact factor: 10.121

7.  Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update.

Authors:  M Maloo; P Abt; R Kashyap; D Younan; M Zand; M Orloff; A Jain; A Pentland; G Scott; A Bozorgzadeh
Journal:  Am J Transplant       Date:  2006-06-19       Impact factor: 8.086

8.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients.

Authors:  S E Cowper; H S Robin; S M Steinberg; L D Su; S Gupta; P E LeBoit
Journal:  Lancet       Date:  2000-09-16       Impact factor: 79.321

9.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.

Authors:  Whitney A High; Reed A Ayers; John Chandler; Gary Zito; Shawn E Cowper
Journal:  J Am Acad Dermatol       Date:  2006-11-09       Impact factor: 11.527

10.  Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease).

Authors:  Julian M Mackay-Wiggan; David J Cohen; Mark A Hardy; Elizabeth H Knobler; Marc E Grossman
Journal:  J Am Acad Dermatol       Date:  2003-01       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.